Your browser doesn't support javascript.
loading
Blood and cerebellar abundance of ATXN3 splice variants in spinocerebellar ataxia type 3/Machado-Joseph disease.
Raposo, Mafalda; Hübener-Schmid, Jeannette; Tagett, Rebecca; Ferreira, Ana F; Vieira Melo, Ana Rosa; Vasconcelos, João; Pires, Paula; Kay, Teresa; Garcia-Moreno, Hector; Giunti, Paola; Santana, Magda M; Pereira de Almeida, Luis; Infante, Jon; van de Warrenburg, Bart P; de Vries, Jeroen J; Faber, Jennifer; Klockgether, Thomas; Casadei, Nicolas; Admard, Jakob; Schöls, Ludger; Riess, Olaf; Costa, Maria do Carmo; Lima, Manuela.
Afiliação
  • Raposo M; IBMC - Instituto de Biologia Molecular e Celular, i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal; Faculdade de Ciências e Tecnologia, Universidade dos Açores, Ponta Delgada, Portugal. Electronic address: msraposo@i3s.up.pt.
  • Hübener-Schmid J; Institute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany; Centre for Rare Diseases, University of Tübingen, Tübingen, Germany. Electronic address: jeannette.huebener@med.uni-tuebingen.de.
  • Tagett R; Bioinformatics Core, Michigan Medicine, University of Michigan, Ann Arbor, MI, USA.
  • Ferreira AF; Faculdade de Ciências e Tecnologia, Universidade dos Açores, Ponta Delgada, Portugal.
  • Vieira Melo AR; Faculdade de Ciências e Tecnologia, Universidade dos Açores, Ponta Delgada, Portugal.
  • Vasconcelos J; Serviço de Neurologia, Hospital do Divino Espírito Santo, Ponta Delgada, Portugal.
  • Pires P; Serviço de Neurologia, Hospital do Santo Espírito da Ilha Terceira, Angra do Heroísmo, Portugal.
  • Kay T; Serviço de Genética Clínica, Hospital D. Estefânia, Lisboa, Portugal.
  • Garcia-Moreno H; Ataxia Centre, Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, University College London, London, UK; Department of Neurogenetics, National Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Foundation Trust, London, UK.
  • Giunti P; Ataxia Centre, Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, University College London, London, UK; Department of Neurogenetics, National Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Foundation Trust, London, UK.
  • Santana MM; Center for Neuroscience and Cell Biology (CNC), University of Coimbra, Coimbra, Portugal; Center for Innovative Biomedicine and Biotechnology (CIBB), University of Coimbra, Coimbra, Portugal; Institute for Interdisciplinary Research, University of Coimbra (IIIUC), Coimbra, Portugal.
  • Pereira de Almeida L; Center for Neuroscience and Cell Biology (CNC), University of Coimbra, Coimbra, Portugal; Center for Innovative Biomedicine and Biotechnology (CIBB), University of Coimbra, Coimbra, Portugal; Faculty of Pharmacy, University of Coimbra (FFUC), Coimbra, Portugal.
  • Infante J; Neurology Service, University Hospital Marqués de Valdecilla-IDIVAL, Universidad de Cantabria, Centro de Investigación en Red de Enfermedades Neurodegenerativas (CIBERNED), Santander, Spain.
  • van de Warrenburg BP; Radboud University Medical Centre, Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, the Netherlands.
  • de Vries JJ; Department of Neurology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
  • Faber J; Department of Neurology, University Hospital Bonn, Bonn, Germany; German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
  • Klockgether T; Department of Neurology, University Hospital Bonn, Bonn, Germany; German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
  • Casadei N; Institute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany; NGS Competence Center Tübingen, Tübingen, Germany.
  • Admard J; Institute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany; NGS Competence Center Tübingen, Tübingen, Germany.
  • Schöls L; Department for Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research and Center for Neurology, University of Tübingen, Germany; German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany.
  • Riess O; Institute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany; Centre for Rare Diseases, University of Tübingen, Tübingen, Germany; NGS Competence Center Tübingen, Tübingen, Germany.
  • Costa MDC; Department of Neurology, Michigan Medicine, University of Michigan, Ann Arbor, MI, USA. Electronic address: mariadoc@med.umich.edu.
  • Lima M; Faculdade de Ciências e Tecnologia, Universidade dos Açores, Ponta Delgada, Portugal. Electronic address: maria.mm.lima@uac.pt.
Neurobiol Dis ; 193: 106456, 2024 Apr.
Article em En | MEDLINE | ID: mdl-38423193
ABSTRACT
Spinocerebellar ataxia type 3 (SCA3)/Machado-Joseph disease (MJD) is a heritable proteinopathy disorder, whose causative gene, ATXN3, undergoes alternative splicing. Ataxin-3 protein isoforms differ in their toxicity, suggesting that certain ATXN3 splice variants may be crucial in driving the selective toxicity in SCA3. Using RNA-seq datasets we identified and determined the abundance of annotated ATXN3 transcripts in blood (n = 60) and cerebellum (n = 12) of SCA3 subjects and controls. The reference transcript (ATXN3-251), translating into an ataxin-3 isoform harbouring three ubiquitin-interacting motifs (UIMs), showed the highest abundance in blood, while the most abundant transcript in the cerebellum (ATXN3-208) was of unclear function. Noteworthy, two of the four transcripts that encode full-length ataxin-3 isoforms but differ in the C-terminus were strongly related with tissue expression specificity ATXN3-251 (3UIM) was expressed in blood 50-fold more than in the cerebellum, whereas ATXN3-214 (2UIM) was expressed in the cerebellum 20-fold more than in the blood. These findings shed light on ATXN3 alternative splicing, aiding in the comprehension of SCA3 pathogenesis and providing guidance in the design of future ATXN3 mRNA-lowering therapies.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Machado-Joseph Limite: Humans Idioma: En Revista: Neurobiol Dis Assunto da revista: NEUROLOGIA Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Machado-Joseph Limite: Humans Idioma: En Revista: Neurobiol Dis Assunto da revista: NEUROLOGIA Ano de publicação: 2024 Tipo de documento: Article